Viral escape and T-cell immunity during ganciclovir treatment of cytomegalovirus infection: Case report of a pancreatico-renal transplant recipient

Transplantation

Volumn 75, Issue 5, 2003, Pages 724-727

  Benz, Christine ^a,d   Holz, Gisela ^a   Michel, Detlef ^b   Awerkiew, Sabine ^a   Dries, Volker ^a   Stippel, Dirk ^a   Goeser, Tobias ^a   Busch, Dirk H ^c  

^a UNIVERSITY OF COLOGNE   (Germany)

^b UNIVERSITY OF ULM   (Germany)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^d UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CYTOKINE; GANCICLOVIR; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; STEROID; TACROLIMUS; TETRAMER;

ADULT; ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC RESISTANCE; ARTICLE; CELLULAR IMMUNITY; CLINICAL ARTICLE; CYTOMEGALOVIRUS INFECTION; GENOTYPE; HUMAN; HUMAN TISSUE; IMMUNOLOGICAL MONITORING; KIDNEY TRANSPLANTATION; PANCREAS TRANSPLANTATION; PRIORITY JOURNAL; RECURRENT INFECTION; T LYMPHOCYTE SUBPOPULATION;

ANTIVIRAL AGENTS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; COLITIS; CYTOMEGALOVIRUS INFECTIONS; GANCICLOVIR; HUMANS; KIDNEY TRANSPLANTATION; MIDDLE AGED; PANCREAS TRANSPLANTATION; RECURRENCE; T-LYMPHOCYTE SUBSETS;

EID: 0037444117     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.TP.0000052664.18029.E6     Document Type: Article

References (10)

1. Jordan ML, Shapiro R, Gritsch HA, et al. Long-term results of pancreas transplantation under tacrolimus immunosuppression. Transplantation 1999; 67(2): 266.
2. Keay S. CMV infection and disease in kidney and pancreas transplant recipients. Transpl Infect Dis 1999; 1(suppl 1): 19.
3. Kaufman DB, Leventhal JR, Gallon LG, et al. Risk factors and impact of cytomegalovirus disease in simultaneous pancreas-kidney transplantation. Transplantation 2001; 72(12): 1940.
4. Lo A, Stratta RJ, Egidi MF, et al. Patterns of cytomegalovirus infection in simultaneous kidney-pancreas transplant recipients receiving tacrolimus, mycophenolate mofetil, and prednisone with ganciclovir prophylaxis. Transpl Infect Dis 2001; 3(1): 8.
5. Sawyer MD, Mayoral JL, Gillingham KJ, et al. Treatment of recurrent cytomegalovirus disease in patients receiving solid organ transplants. Arch Surg 1993; 128(2): 165.
6. Limaye AP, Corey L, Koelle DM, et al. Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants. Lancet 2000; 356(9230): 645.
7. Rosen HR, Benner KG, Flora KD, et al. Development of ganciclovir resistance during treatment of primary cytomegalovirus infection after liver transplantation. Transplantation 1997; 63(3): 476.
8. Emery VC. Prophylaxis for CMV should not now replace pre-emptive therapy in solid organ transplantation. Rev Med Virol 2001; 11(2): 83.
9. Michel D, Hohn S, Haller T, et al. Aciclovir selects for ganciclovir-cross-resistance of human cytomegalovirus in vitro that is only in part explained by known mutations in the UL97 protein. J Med Virol 2001; 65(1): 70.
10. Benz C, Utermohlen O, Wulf A, et al. Activated virus-specific T cells are early indicators of anti-CMV immune reactions in liver transplant patients. Gastroenterology 2002; 122(5): 1201.